MK-677 (Ibutamoren): Oral GH Secretagogue Research Overview

# MK-677 (Ibutamoren): Oral GH Secretagogue Research Overview

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

MK-677 (Ibutamoren mesylate) is a non-peptide, orally active agonist of the ghrelin receptor (GHS-R1a) developed by Merck Research Laboratories in the 1990s. Unlike peptide GH secretagogues (Ipamorelin, GHRP-6, CJC-1295), MK-677 is orally bioavailable — a pharmacokinetic property that makes it uniquely suited for research protocols requiring convenient, non-injectable GH axis stimulation.

Pharmacology

Mechanism: MK-677 activates GHS-R1a, the ghrelin receptor, stimulating GH secretion from pituitary somatotrophs through the same pathway as peptide GHRPs. GHS-R1a activation triggers IP3/calcium signaling in somatotrophs, leading to GH vesicle exocytosis.

Oral bioavailability: Approximately 60-70% in humans — substantially higher than any peptide GHRP, which have negligible oral bioavailability due to gastrointestinal peptidase degradation.

Half-life: Approximately 4-6 hours in humans, enabling once-daily dosing that produces sustained GH and IGF-1 elevation throughout the day.

Selectivity: MK-677 is less selective than Ipamorelin — it produces dose-dependent cortisol elevation and increases appetite, consistent with its GHS-R1a agonism at hypothalamic receptors mediating these effects.

Clinical Trial Evidence

MK-677 has been evaluated in multiple human clinical trials, providing a more robust human evidence base than most research peptides.

Svensson et al. (1998) — Obese adults: 2-month treatment with 25 mg/day MK-677 increased 24-hour mean GH concentration by 97% and IGF-1 by 52% above baseline. Fat-free mass increased by 1.6 kg and basal metabolic rate increased by 9%.

Nass et al. (2008) — Elderly adults: 2-year treatment with 25 mg/day MK-677 in adults aged 60-81 years increased IGF-1 levels by 60% above baseline. Lean body mass increased by approximately 1.5 kg. However, adverse effects included increased fasting glucose (+0.3 mmol/L), increased fasting insulin, and worsening insulin resistance — effects consistent with GH's anti-insulin actions.

Copeland et al. (2020) — Older adults with hip fracture: 24-week treatment with 25 mg/day MK-677 did not significantly improve functional outcomes in older adults recovering from hip fracture, despite increasing IGF-1 levels.

Murphy et al. (1998) — Elderly adults: 2-year treatment with MK-677 in healthy elderly adults increased GH and IGF-1 levels and improved body composition, with the primary adverse effects being increased appetite and edema.

Insulin Resistance Concern

A consistent finding across MK-677 clinical trials is the development of insulin resistance with sustained use. GH has well-characterized anti-insulin effects — it promotes lipolysis and reduces peripheral glucose uptake. Sustained GH elevation from MK-677 produces corresponding increases in fasting glucose and insulin.

This insulin resistance effect is a significant consideration for research protocols, particularly in metabolic research where glucose homeostasis is a primary outcome variable. Researchers should monitor glucose and insulin parameters in any protocol using MK-677.

Comparison with Injectable GHRPs

The primary advantage of MK-677 over injectable GHRPs (Ipamorelin, GHRP-6) is oral bioavailability. For research protocols requiring chronic GH axis stimulation over weeks to months, once-daily oral MK-677 is substantially more practical than daily injections.

The primary disadvantage is lower selectivity — MK-677 produces cortisol elevation and appetite stimulation that Ipamorelin does not. For short-term studies where these effects are confounding variables, injectable Ipamorelin may be preferable.

Research Applications

MK-677 has been studied for: - GH deficiency models: As a non-injectable alternative to GH replacement - Sarcopenia research: Effects on lean body mass in elderly subjects - Bone density: Effects on bone turnover markers and density - Sleep: GH-dependent effects on slow-wave sleep architecture - Cognitive function: IGF-1-mediated effects on hippocampal function

References

1. Svensson, J., et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362–369.
2. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–611.
3. Murphy, M.G., et al. (1998). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research, 14(7), 1182–1188.